Metformin and Rapamycin Interaction: Synergistic | Peptide Database

Join others researching Pramipexole — share findings, ask questions, and learn from real experiences Pramipexole is a non-ergoline dopamine agonist with preferential affinity for the D3 dopamine receptor subtype. It is FDA-approved under the brand names Mirapex and Mirapexin for the treatment of Parkinson's disease and restless legs syndrome (RLS). In the bodybuilding and performance enhancement context, pramipexole serves as an alternative to cabergoline for managing prolactin elevation caused by 19-nor anabolic steroids such as nandrolone (Deca-Durabolin, NPP) and trenbolone. While less potent than cabergoline at suppressing prolactin, pramipexole is typically cheaper and more readily available, making it a practical option when cabergoline is difficult to source. Its shorter half-life of approximately 8 hours necessitates daily dosing (usually at bedtime), and it must be titrated slowly from a low starting dose to minimize side effects -- particularly nausea, which is common during initiation. Pramipexole is generally considered a second-choice prolactin management agent behind cabergoline due to its lower potency, shorter duration, and less favorable side effect profile at the doses sometimes needed for adequate prolactin suppression. Pramipexole exerts its prolactin-suppressing effects by acting as a full agonist at dopamine D2 and D3 receptors, with a marked preference for the D3 subtype. In the anterior pituitary, prolactin secretion by lactotroph cells is tonically inhibited by hypothalamic dopamine acting on D2 receptors. Pramipexole stimulates these D2 receptors to suppress prolactin gene transcription, synthesis, and release. Its preferential D3 activity also contributes to its clinical effects in Parkinson's disease and may account for some of its neuropsychiatric side effects, particularly impulse control disorders, which are mediated through mesolimbic D3 signaling pathways. In the context of 19-nor steroid use, nandrolone and trenbolone elevate prolactin through progestogenic activity at the pituitary, and pramipexole counteracts this by restoring dopaminergic inhibition. However, because pramipexole has lower D2 affinity and a much shorter half-life than cabergoline, higher relative doses and more frequent administration are needed to achieve comparable prolactin suppression.

Join others researching Bronchogen — share findings, ask questions, and learn from real experiences Bronchogen is a Khavinson bioregulator tetrapeptide (AEDL) with primary effects on the bronchopulmonary system. Developed at Russia's St. Petersburg Institute of Bioregulation and Gerontology by Professor Vladimir Khavinson, it targets bronchial tissue and supports respiratory function. Like other Khavinson peptides, Bronchogen penetrates cell nuclei to influence gene expression related to respiratory tissue maintenance and repair. Bronchogen works through epigenetic regulation by penetrating cell and nuclear membranes to interact with DNA and modulate gene expression in bronchial tissue. It regulates protein synthesis in bronchopulmonary cells, supporting maintenance and repair of respiratory epithelium. The tetrapeptide structure allows efficient cellular uptake and tissue-specific targeting to bronchial structures.